News

Medical News Today

Medical News Today reports that an experimental weight-loss drug may improve sleep apnea symptoms. The provided excerpt contains only the headline and is too thin to summarize findings or identify the drug.

Foreign Policy Journal

The Foreign Policy Journal headline claims Lilly's Retatrutide delivered twice the weight loss of Ozempic, increasing competitive pressure on Novo Nordisk. The excerpt only repeats the headline and is too thin to substantively summarize or assess the comparison.

ClinicalTrials.gov: peptide AND aging

A recruiting study listed on ClinicalTrials.gov will evaluate a 16-week weight-management intervention in adults aged 60 or older with low physical activity and excess body fat. Researchers will compare resistance training alone with added group cognitive behavioral therapy and higher-protein nutritional guidance; the excerpt describes no peptide intervention.

ClinicalTrials.gov: peptide AND aging

A recruiting randomized trial listed on ClinicalTrials.gov aims to test a 12-week diet and exercise intervention in 80 adults aged 50 and older with obesity and insulin resistance. Researchers will assess body composition, muscle function, and energy balance; the excerpt describes no peptide intervention or results.

ClinicalTrials.gov: survodutide

A ClinicalTrials.gov listing describes an active, non-recruiting study comparing survodutide with semaglutide in adults aged 18–65 with obesity. The randomized study tests whether survodutide improves energy use and fat breakdown, with participants followed for 8–10 months.

ClinicalTrials.gov: survodutide

ClinicalTrials.gov lists as completed a study testing survodutide (BI 456906) for weight loss in Japanese adults with obesity disease. Participants were randomly assigned to two survodutide groups or a placebo group; the provided excerpt does not report results.

ClinicalTrials.gov: survodutide

ClinicalTrials.gov lists a study of survodutide (BI 456906) in Chinese adults with overweight or obesity as completed. The trial randomly assigned participants to three groups to compare survodutide with placebo; the provided excerpt contains no results.

ClinicalTrials.gov: survodutide

ClinicalTrials.gov lists SYNCHRONIZE-MASLD as completed, a study testing survodutide against placebo for reducing liver fat and body weight in adults with overweight or obesity and presumed or confirmed NASH. Participants were assigned randomly to two groups; the provided excerpt contains no results.